Title: Current role of clopidogrel in the therapy of coronary heart disease
- Piotr Zając, Włodzimierz Grabowicz
- Review articles
- Polish Journal of Cardiology
- Start page:
- Final page:
- clopidogrel, coronary artery disease, antiplatelet agents
Antiplatelet therapy is an essential element of treatment of both forms of coronary heart disease: stable angina as well as acute coronary syndromes. The acetylsalicylic acid has established position but also the drugs from thienopyridine class such as clopidogrel are receiving general recognition. Clopidogrel has recently become the subject of many studies the results of which are very controversial. The study is a presentation of clopidogrel as an antiplatelet drug in the therapy of coronary heart disease in the context of actual studies and guidelines. We analyse the phenomenon of “variable response to clopidogrel”/“clopidogrel resistance” and the related problem of optimal loading dose of drug. The ontroversial issue is also a problem of giving the clopidogrel after coronary artery bypass grafting and after implantation of particular type of stent. We also present a current information about drugs which may become clopidogrel’s competitors such as prasugrel. At the end we present results from studies about interactions between clopidogrel and proton pump inhibitors in the context of new guidelines concerning reduction the gastrointestinal risks of antiplatelet therapy.